Skip to content

Bioinformatics and Computational Biology Short Notes

One-page CSIR NET revision: databases, scoring matrices, BLAST, phylogenetics, annotation, variants, force fields, AlphaFold, drug design and systems biology.

  • 10 min read
  • Updated
On this page · 9 sections
  1. Databases and Formats
  2. Alignment and Database Search
  3. Phylogenetics and Comparative Genomics
  4. Annotation and Variation
  5. Modelling and Structure Prediction
  6. Drug Design
  7. Systems Biology and Personalised Medicine
  8. Numbers to Have Ready
  9. Traps in One Line Each

The unit on one page. For explanations and worked problems, go back to the chapter: Bioinformatic Resources, Sequence Alignment, Phylogenetics, Comparative Genomics and Annotation, Molecular Modelling and Structure Prediction, Computer-Aided Drug Design and Systems Biology and Personalised Medicine.

Databases and Formats

FactDetail
Primary vs secondaryPrimary = submitted, redundant (GenBank, SRA, PDB, GEO); secondary = curated or derived (RefSeq, Swiss-Prot, Pfam, CATH)
INSDCGenBank (NCBI, USA), ENA (EMBL-EBI, UK), DDBJ (NIG, Japan); same accessions; daily exchange
VersionsAB123456.2 = second version of the sequence
RefSeq prefixesNC chromosome, NG gene region, NM mRNA, NR ncRNA, NP protein; X = predicted (XM, XP)
UniProtKBSwiss-Prot reviewed, TrEMBL automatic; UniParc archive; UniRef100/90/50 clusters
ExpressionGEO (GPL platform, GSM sample, GSE series, GDS dataset), ArrayExpress, Expression Atlas, GTEx; MIAME, MINSEQE
PDBExperimental structures; wwPDB (RCSB, PDBe, PDBj, BMRB); EMDB maps; mmCIF standard; 4-character IDs
Structure qualityResolution lower = better; R-free guards over-fitting; B-factor = mobility
AlphaFold DBPredicted models, with pLDDT
Pattern/familyPROSITE (regex + profiles), PRINTS (fingerprints), BLOCKS (ungapped blocks → BLOSUM), Pfam (HMMs), SMART, CDD, InterPro (integrates)
PROSITE syntaxx any; [ST] either; {P} not P; x(2,4) range; < N-terminus, > C-terminus; N-glycosylation N-{P}-[ST]-{P}
GOMolecular function, biological process, cellular component; DAG; IEA = electronic, unreviewed
Pathways / interactionsKEGG, Reactome, BioCyc / STRING, BioGRID, IntAct; SBML models in BioModels
Variants / diseasedbSNP (rs), dbVar, ClinVar, OMIM, gnomAD, COSMIC
Model organismsFlyBase, WormBase, SGD, TAIR, MGI, ZFIN
FormatsFASTA (>), GenBank flat file, FASTQ (4 lines), SAM/BAM/CRAM, VCF, GFF3/GTF, BED 0-based half-open, PDB/mmCIF
PhredQ = −10 log₁₀ P; Q20 = 1%, Q30 = 0.1%, Q40 = 0.01%; Phred+33 (‘I’ = Q40)
CoverageC = LN/G; uncovered fraction e^(−C)
FactDetail
HomologyCommon ancestry, yes or no; identity and similarity are percentages
Orthologue / paralogueSpeciation / duplication; xenologue = HGT; analogue = convergence
In-/out-paraloguesDuplication after / before the speciation considered
Dot plotDiagonal = similarity; parallel diagonals = repeats; offsets = indels
Log-oddss = (1/λ) ln(q_ab / p_a p_b)
PAMDayhoff; PAM1 = 1% change; extrapolated; higher PAM for distant
BLOSUMHenikoff 1992; BLOCKS clustered at X%; lower BLOSUM for distant; BLOSUM62 default
BLOSUM62 diagonalW–W 11, C–C 9 (rare residues score highest)
Affine gapW = G_o + k G_e; blastp 11/1
Needleman–WunschGlobal; F(i,0) = ig; result bottom-right
Smith–WatermanLocal; floor 0; start at highest cell; stop at 0
DP cost∝ m × n
FASTAktup 2 protein / 6 DNA; init1 → initn → opt (banded SW)
BLASTWords (protein 3 classic, blastn 11, megablast 28); neighbourhood threshold T; extension; HSP; two-hit
BLAST programsblastn, blastp, blastx (query translated), tblastn (database translated), tblastx (both)
E-valueE = Kmn e^(−λS); ∝ database size; lower = more significant
Bit scoreS′ = (λS − ln K)/ln 2; E = mn 2^(−S′); database-independent
PSI-BLASTIterative PSSM; remote homologues; profile drift
MSAProgressive (ClustalW, guide tree; “once a gap, always a gap”), iterative (MUSCLE, MAFFT), consistency (T-Coffee)
Clustal marks* identical, : strong, . weak
ProfilesPSSM; profile HMM (match, insert, delete states)
Sequence logoIC = log₂N − H; DNA max 2 bits

Phylogenetics and Comparative Genomics

FactDetail
GroupsMonophyletic (clade), paraphyletic, polyphyletic
Tree typesCladogram (topology), phylogram (change), chronogram (time, ultrametric)
RootingOutgroup or midpoint
Tree countsUnrooted (2n − 5)!!, rooted (2n − 3)!!; 4 taxa 3/15; 5 taxa 15/105
JC69d = −¾ ln(1 − 4p/3); p = 0.30 → 0.383; saturation at 0.75
K2PTransitions vs transversions
ModelsJC, K2P, F81, HKY, GTR, +Γ, +I; AIC/BIC
UPGMAClock; rooted ultrametric; average distances weighted by cluster size
NJSaitou and Nei 1987; no clock; unrooted
ParsimonyFewest changes; informative sites; long-branch attraction
ML / BayesianP(data given tree and model) / posterior via MCMC
BootstrapResample columns with replacement; % support (often ≥ 70% taken as good)
ClockPairwise d = 2rt
dN/dS< 1 purifying, ≈ 1 neutral, > 1 positive
Comparative genomicsSynteny, collinearity, reciprocal best hits, COG/eggNOG, CNEs (phylogenetic footprinting), HGT signals
Pan-genomeCore + accessory + unique; open vs closed
C-value paradoxGenome size does not track complexity

Annotation and Variation

FactDetail
Structural vs functionalWhere genes are vs what they do
Prokaryotic findersORF + Shine–Dalgarno; GeneMark, Glimmer (interpolated Markov models), Prodigal
Eukaryotic findersGT–AG, Kozak, CpG islands, AATAAA; GENSCAN, AUGUSTUS (GHMMs); RNA-seq evidence; MAKER/BRAKER
Random ORFsP(no stop in n codons) = (61/64)ⁿ; mean about 21 codons
ncRNAtRNAscan-SE, Rfam
Sn / Sp (gene finding)TP/(TP + FN) / TP/(TP + FP)
VariantsSNV (SNP if MAF ≥ 1%), indel, STR, CNV, SV; germline vs somatic
HGVSc., g., p.; CFTR c.1521_1523delCTT, p.(Phe508del)
PipelineFASTQ → BWA/Bowtie2 → BAM → GATK/bcftools → VCF → VEP/SnpEff
PredictionSIFT (≤ 0.05 deleterious), PolyPhen-2, CADD
LDD = p_AB − p_A p_B; D′ = D/D_max; r² = D²/(p_A p_a p_B p_b)
GWASP < 5 × 10⁻⁸; Manhattan and QQ plots; PCA for stratification; OR = ad/bc; hit ≠ causal variant

Modelling and Structure Prediction

FactDetail
MM vs QMMM cannot break bonds; QM/MM for reactions (Nobel 2013: Karplus, Levitt, Warshel)
Force fieldBonds + angles + torsions + impropers + LJ 12-6 + Coulomb
Lennard-JonesZero at σ; minimum −ε at 2^(1/6)σ ≈ 1.12σ
Coulomb1389 q₁q₂/(ε_r r) kJ/mol (r in Å); ε_r ≈ 4 interior, ≈ 80 water
Force fieldsAMBER, CHARMM, OPLS-AA (all-atom); GROMOS (united-atom); MARTINI (coarse); MMFF94, GAFF (ligands)
SolventExplicit TIP3P, SPC/E; implicit PB, GB
MinimisersSteepest descent (robust), conjugate gradient, Newton–Raphson/L-BFGS; local minimum only
Monte CarloMetropolis: accept uphill with e^(−ΔE/kT)
MDF = −∇U; Verlet; 1–2 fs (SHAKE/LINCS); PBC; PME; Maxwell–Boltzmann start
EnsemblesNVE; NVT (thermostat); NPT (thermostat + barostat)
AnalysisRMSD (drift), RMSF (flexibility), Rg (compactness), PCA, MM-PBSA, FEP
Enhanced samplingReplica exchange, metadynamics, umbrella sampling, steered MD
SCOPClass → Fold → Superfamily (probable ancestry) → Family (clear relationship)
CATHClass (1 α, 2 β, 3 α–β, 4 few SS) → Architecture → Topology → Homologous superfamily
Levinthal3^100 ≈ 5 × 10⁴⁷; folding funnel
1D predictionChou–Fasman, GOR, PSIPRED (profiles); TM helices by hydropathy (~20 residues); SignalP
Homology modellingTemplate → alignment → backbone → loops → side chains (rotamers) → refine → validate; MODELLER, SWISS-MODEL
Identity guide> 50% high accuracy; 30–50% useful; < 30% twilight zone
ThreadingFold library + knowledge-based potentials; Phyre2, I-TASSER
Ab initioRosetta fragment assembly; coevolution contacts
AlphaFold2MSA + Evoformer + structure module; CASP14 (2020); Nobel 2024 (Hassabis, Jumper; Baker for design)
pLDDT> 90 very high; 70–90 confident; 50–70 low; < 50 very low (often disorder)
PAERelative position confidence; high between domains = orientation uncertain
SuccessorsAlphaFold-Multimer, AlphaFold3 (ligands, nucleic acids), RoseTTAFold, ESMFold (single sequence)
ValidationRamachandran (PROCHECK, MolProbity), ProSA, QMEAN; RMSD, GDT_TS, TM-score (> 0.5 same fold)

Drug Design

FactDetail
PipelineTarget → hit → lead → optimisation → preclinical → Phase I–III
Chemical databasesPubChem (SID, CID, AID), NCI collections and the NCI-60 cell-line panel, ChEMBL, DrugBank, ZINC, BindingDB, PDBbind, CSD
NotationsSMILES, InChI/InChIKey, MOL/SDF, SMARTS (substructure patterns)
Affinity\(K_d\) small = tight; \(\Delta G^{\circ} = RT\ln K_d\); 10× affinity ≈ 5.7 kJ mol⁻¹ (1.36 kcal mol⁻¹)
\(IC_{50}\) → \(K_i\)Cheng–Prusoff \(K_i = IC_{50}/(1 + [S]/K_m)\)
Binding forcesH-bonds and ionic (enthalpic, desolvation cost), hydrophobic effect (entropic, dominant), van der Waals, conformational entropy loss
Binding modelsLock and key, induced fit, conformational selection
Ligand efficiency\(LE = -\Delta G/N_{\text{heavy}}\)
SBDDNeeds the target structure; prepare → site → dock → rescore → assay → new structure
DockingSearch (systematic, genetic, Monte Carlo) + scoring (force-field, empirical, knowledge-based, ML); receptor usually rigid; redocking RMSD < 2 Å validates; scores ≠ free energies
Better energeticsMM-PBSA/GBSA, FEP, thermodynamic integration
Virtual screening\(\text{EF}_{x\%}\) = (actives in top x%)/(expected); ROC-AUC; fragment-based, de novo, repurposing
LBDDSimilar property principle; descriptors 0D–3D (log P, TPSA, σ, \(E_s\)); Tanimoto \(T = c/(a + b - c)\)
Pharmacophore3D feature arrangement (donor, acceptor, hydrophobe, aromatic, ±ionisable); scaffold hopping; bioisosteres
QSARHansch (log P, σ, \(E_s\)), Free–Wilson (additive); parabolic log P optimum
3D-QSARCoMFA (steric + electrostatic fields + PLS), CoMSIA
QSAR validation\(R^2\) (fit) vs \(q^2 > 0.5\) vs external \(R^2_{pred}\); y-randomisation; applicability domain
Rule of fiveMW > 500, log P > 5, donors > 5, acceptors > 10; two or more violations flag poor oral absorption
Other filtersVeber (rotatable bonds ≤ 10, TPSA ≤ 140 Ų), rule of three (fragments), PAINS
ADMETSolubility, permeability (Caco-2, PAMPA), bioavailability, protein binding, BBB and P-gp, CYP450 metabolism and interactions, \(t_{1/2} = 0.693V_d/CL\), toxicity (hERG, Ames)

Systems Biology and Personalised Medicine

FactDetail
Systems biologyNetworks + models + high-throughput data; measure → model → predict → test
Emergent propertiesRobustness, bistability, oscillation, ultrasensitivity, adaptation
NetworksPPI (STRING, BioGRID, IntAct), gene regulatory, metabolic (KEGG, MetaCyc), signalling (Reactome), co-expression (WGCNA), disease
Graph termsDegree, hub, betweenness (bottleneck), clustering coefficient, module
Scale-free\(P(k)\sim k^{-\gamma}\); robust to random loss, fragile to hub attack; small-world = short paths + clustering
MotifsNegative autoregulation (fast, low noise); positive autoregulation (bistable); coherent FFL (delay/filter); incoherent FFL (pulse); SIM; DOR; delayed negative feedback (oscillation)
Model typesODE, stochastic (Gillespie), Boolean (attractors), constraint-based (FBA), agent-based, PDE
Rate lawsMass action; Michaelis–Menten; Hill \(n > 1\) ultrasensitive
StandardsSBML, BioModels, SBGN; COPASI, COBRA, CellDesigner
FBA\(\mathbf{Sv} = 0\) + flux bounds + objective (biomass); no kinetic parameters, no time course; optima usually non-unique; FVA, pFBA, dynamic FBA
Data science traps\(p \gg n\); multiple testing (Bonferroni = FWER, Benjamini–Hochberg = FDR/q); batch effects; FAIR data
MethodsPCA (linear) vs t-SNE/UMAP (visualisation only); clustering; differential expression; GO/pathway enrichment; LASSO, random forest, boosting, neural networks
ML disciplineTrain/validation/held-out test, feature selection inside cross-validation, external cohort; class imbalance → use sensitivity, specificity, PR-AUC, ROC-AUC
Disease modellingDisease modules, network pharmacology, driver vs passenger, SIR models (\(R_0\), herd immunity \(1 - 1/R_0\)), PBPK, digital twins
Digital healthEHR, telemedicine, wearables, decision support; FHIR/HL7, ICD, SNOMED CT, LOINC; privacy, bias, regulation, federated analysis
Personalised medicinePharmacogenomics (metaboliser status, HLA risk alleles, companion diagnostics), molecular stratification, targeted therapy, polygenic risk scores, liquid biopsy, ACMG/AMP interpretation
Test arithmeticSensitivity and specificity are prevalence-independent; PPV depends on prevalence; for rare conditions specificity dominates PPV
ELSIConsent, incidental findings, right not to know, discrimination, data sovereignty, equity, ancestry bias in reference data

Numbers to Have Ready

QuantityValue
Q30 error per base10⁻³
Phred+33 ‘I’Q40
e^(−3)0.050
Bit score 50, m = 300, n = 10⁹E ≈ 2.7 × 10⁻⁴
Extra raw score to cut E tenfoldln 10/λ
JC d at p = 0.1 / 0.3 / 0.60.107 / 0.383 / 1.207
(61/64)^1000.008
2^(1/6)1.12
100 ns at 2 fs5 × 10⁷ steps
RT at 300 K2.49 kJ/mol
Metropolis, ΔE = 5 kJ/mol, 300 K0.13
RT at 298 K2.48 kJ/mol; RT ln 10 = 5.7 kJ/mol
ΔG° at K_d = 1 nM−51 kJ/mol
Tanimoto, a = 60, b = 80, c = 400.40
PPV at 1% prevalence, 99% sensitivity, 95% specificity17%
Bonferroni α for 20,000 tests2.5 × 10⁻⁶

Traps in One Line Each

  • “40% homologous” is wrong usage; say 40% identical.
  • PAM250 and BLOSUM45 are for distant sequences.
  • E-value rises with database size; bit score does not.
  • Smith–Waterman traceback starts at the maximum cell.
  • Human α-globin vs mouse β-globin: paralogues.
  • UPGMA assumes a clock; NJ does not.
  • Bootstrap % is support under resampling, not the probability of truth.
  • GWAS lead SNP is usually a marker in LD, not the cause.
  • Minimisation finds a local minimum, at 0 K, with no time axis.
  • Same SCOP fold does not prove homology; same superfamily implies it.
  • Low pLDDT often means disorder; inter-domain orientation needs PAE.
  • AlphaFold2 models contain no ligands.
  • A large K_d means weak binding, not tight.
  • The rule of five flags trouble at two violations, and says nothing about potency or safety.
  • Docking ranks poses well and affinities poorly; every hit still needs an assay.
  • A high R² proves nothing; check q², an external test set and the applicability domain.
  • FBA gives steady-state fluxes, not time courses, and its optimum is usually not unique.
  • Scale-free networks are robust to random failure and fragile at hubs.
  • For a rare disease, most positives from a good test are false: PPV follows prevalence.
Advertisement
Advertisement